Amnion cell therapies
As the world’s leading research group on amnion epithelial cells in regenerative medicine, the Maternal and Perinatal Research Group has led the application of amnion cells as a therapy for preterm lung disease. The team will commence a world first clinical trial in 2014. The amnion cell research is a large component of the Cell Therapy and Regenerative Medicine Theme within the Centre, reflected by the multiple collaborations between groups within that theme including Dr Rebecca Lim’s Amnion Cell Biology group and Professor Graham Jenkin’s Cell Therapy group).The Group also collaborates closely with Associate Professor Tim Moss’ Fetal and Neonatal Health group on large animal models of lung injury and the application of amnion cells. The Group is now extending the research application of amnion cells to other conditions of the extreme preterm infant including necrotizing enterocolitis, using animal models to direct the design of future clinical trials.
Professor Bill Sievert – Clinician Scientist, Director of Gastrointestinal and Liver Unit, Monash Health and Monash University
Associate Professor Tim Moss – NHMRC Senior Research Fellow, Department of Obstetrics and Gynaecology, Monash University
Associate Professor Chris Sobey – NHMRC Senior Research Fellow, Department of Pharmacology, Monash University
Professor Claude Bernard – Monash Immunology and Stem Cell Labs, Monash University
Professor Daniel Chambers – Thoracic and Transplant Physician, School of Medicine, University of Queensland